ARGX
Argen X SE
BIOTECHNOLOGY · HEALTHCARE
argenx NV, based in Breda, the Netherlands, is a forward-thinking clinical-stage biotechnology company focused on delivering transformative antibody-based treatments for severe autoimmune diseases, hematological disorders, and various cancers. Leveraging its proprietary technology platform, argenx i...
$893.52
-0.60% ($5.42)
Volume
333,159
52W High
$934.62
52W Low
$510.06
Market Cap
$49.30B
What to Watch This Quarter
Based on historical dataConsensus EPS
$5.20
Whisper EPS
$5.64
8.5% above consensus
Last Quarter
$4.70
Current Streak
7 Beats
Avg Surprise (4Q)
+19.17%
Next Earnings Report
Reports in 38 days
Price Chart
EPS History: Consensus vs Actual
Last 12 quartersPrice Movement Around Earnings
Q1 2026
May 7, 2026
1-Day:
-0.65%
5-Day:
+3.24%
Q4 2025
Feb 26, 2026
1-Day:
-0.60%
5-Day:
-2.96%
Q3 2025
Oct 30, 2025
1-Day:
-0.23%
5-Day:
+1.36%
Q2 2025
Jul 31, 2025
1-Day:
+0.52%
5-Day:
+0.68%
Revenue & Financial Performance
Revenue Whisper
$2.60B
TWN Proprietary Estimate
Last Quarter Revenue
$1.30B
+64.2% YoY
Gross Margin
90.7%
Net Margin: 28.2%
| Quarter | Revenue | YoY Growth | Gross Margin | Op Margin | Net Income |
|---|---|---|---|---|---|
| Q1'26 | $1.30B | +64.2% | 90.7% | 30.4% | $366.0M |
| Q4'25 | $2.41B | +78.7% | 88.8% | 27.4% | $874.9M |
| Q3'25 | $1.13B | +96.6% | 90.3% | 31.1% | $344.3M |
| Q2'25 | $1.75B | +94.3% | 88.5% | 17.8% | $418.1M |
| Q1'25 | $790.7M | +97.2% | 89.8% | 17.9% | $169.5M |
| Q4'24 | $1.35B | +77.7% | 50.6% | 8.7% | $865.6M |
| Q3'24 | $573.2M | +73.8% | 89.7% | 2.5% | $91.4M |
| Q2'24 | $901.9M | +76.5% | 47.2% | -15.4% | -$32.5M |
Company Information
Symbol
ARGX
Company
Argen X SE
Market Cap
$49.30B
Sector
HEALTHCARE
Next Earnings
Jul 23, 2026
Also Reporting Soon
Companies reporting earnings around the same time as ARGX
HEALTHCARE Stocks
Other healthcare companies with earnings data
More in BIOTECHNOLOGY
Compare ARGX with competitors
Side-by-side earnings comparison